Our findings revealed that PCSK6 inactivation could suppress liver metastasis efficiently, and PCSK6 might serve as a novel molecular target for improving the therapeutic efficacy of liver metastasis in pancreatic cancer. This evidence concerns the gene PCSK6 and familial pancreatic carcinoma.